Company: BDRX
Filing Date: 2025-04-29
Form Type: POS AM
Source: 0001214659-25-006581
Chunk: 137

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-29
Form: POS AM
Chunk 137
---
 6-K, filed with the SEC on April 26, 2024).    |
| 10.13  | Form of Warrant Letter Agreement (incorporated by reference to Exhibit 10.1 of the Company’s Report on Form 6-K, filed with the SEC on May 22, 2024).                                                                                                                                       |
| 10.14  | Form of Securities Purchase Agreement, dated July 18, 2024, by and between Biodexa Pharmaceuticals PLC and the investors identified on the signature pages thereto (incorporated by reference to Exhibit 10.1 of the Company’s Report on Form 6-K, filed with the SEC on July 19, 2024).    |
| 10.15  | Placement Agency Agreement, dated July 18, 2024, by and between Biodexa Pharmaceuticals PLC and Ladenburg Thalmann & Co. Inc. (incorporated by reference to Exhibit 10.2 of the Company’s Report on Form 6-K, filed with the SEC on July 19, 2024).                                         |
| 10.16  | Promissory Note issued to C/M Capital Master Fund, LP, dated as of December 20, 2024 (incorporated by reference to Exhibit 10.1 to the Company’s Report on Form 6-K, filed with the SEC on December 27, 2024).                                                                              |
| 10.17  | Securities Purchase Agreement, dated January 15, 2025, by and between C/M Capital Master Fund, LP, and Biodexa Pharmaceuticals PLC (incorporated by reference to Exhibit 10.1 to the Company’s Report on Form 6-K, filed with the SEC on January 17, 2025).                                 |
| 10.18  | Registration Rights Agreement, dated January 15, 2025, by and between C/M Capital Master Fund, LP, and Biodexa Pharmaceuticals PLC (incorporated by reference to Exhibit 10.2 to the Company’s Report on Form 6-K, filed with the SEC on January 17, 2025).                                 |
| 19.1   | Insider Trading Policy (incorporated by reference to Exhibit 11.1 of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 11, 2025).                                                                                                  |
|